Hiam Chemaitelly, ICEID 2022: COVID-19 vaccine effectiveness against SARS-CoV-2 variants
The COVID-19 pandemic remains an international public health emergency, and the emergence of new SARS-CoV-2 variants highlights concerns regarding COVID-19 breakthrough infections. Understanding emerging SARS-CoV-2 variants is especially important as the medical and public health community seeks to contain COVID-19. In this interview, Dr Hiam Chemaitelly (Weill Cornell Medicine-Qatar, Ar-Rayyan, Qatar) talked to us about […]
Michael Gordon, ICEID 2022: Oral sabizabulin reduces mortality in hospitalized patients with COVID-19 at high risk for acute respiratory distress syndrome
Sabizabulin is a microtubule disruptor initially developed as an anti-cancer agent that is being repurposed to treat COVID-19. The VERU-111 clinical trial (NCT04842747), which investigates the use of oral sabizabulin on hospitalized patients with COVID-19, is discussed in this touchRESPIRATORY interview with Dr Michael Gordon (HonorHealth Research Institute). ‘Oral sabizabulin reduces mortality in hospitalized patients […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!